Tag: Hepatitis
Optimal MELD Threshold for HCV Tx Pre-Liver Transplant 23 to 27
Treating HCV before liver transplant increased life expectancy if MELD was ≤27
HOMA2-IR Tied to Hepatocellular Carcinoma Risk in Hepatitis B
HOMA2-IR independently linked to HCC in patients without overt metabolic abnormalities
Ledipasvir-Sofosbuvir Safe for Kidney Recipients With HCV
SVR12 for all kidney transplant recipients with HCV genotype 1, 4 after 12 or 24 weeks of treatment
Probable Interaction ID’d for PrOD, Ribavirin With Warfarin
Case report shows probable interaction for ribavirin with paritaprevir/ritonavir/ombitasvir+dasabuvir
Acute Hepatitis Described With Excessive Energy Drink Intake
Patient reported drinking four to five energy drinks per day for three weeks before admission
HBV, HCV Coinfection Ups Non-Hodgkin Risk in ART-Treated HIV
Increased risk for NHL for HIV-infected patients receiving ART with chronic coinfection with HBV, HCV
Liver Stiffness Linked to Hepatic Events, Death in Hepatitis B
Metabolic syndrome ups risk of cardiovascular events, not hepatic events or death in chronic hep B
Most Patients Prefer Oral Dual Therapy in Chronic Hepatitis C
High response rate for dual therapy among cohort of patients with predominant genotype 3
Interferon-Free, Tailored Tx Beneficial in HCV-Associated MC
Guideline-tailored therapy highly effective, safe for hepatitis C virus-associated mixed cryoglobulinemia
Elbasvir-Grazoprevir Effective for HCV With Opioid-Agonist Tx
High rates of sustained virologic response at 12 wks, regardless of drug use at baseline or during tx
